• Home
  • Covid-19
  • Tools
    • Introduction to the Tools
    • Model Government Use Licences
    • Model Uses of Paragraph 7 or “LDC Waiver”
    • Special Compulsory Licences for Export of Medicines
    • Options for Regional Economic Communities
    • Voluntary Licences
  • TRIPS Flexibilities Database
  • Resources
    • Briefs & Briefing Documents
    • Publications
    • Tools
    • Useful Links
    • All Resources
  • Blog
  • About
Search
Medicines Law & Policy Research and resources on intellectual property and health
  • Home
  • Covid-19
  • Tools
    • Introduction to the Tools
    • Model Government Use Licences
    • Model Uses of Paragraph 7 or “LDC Waiver”
    • Special Compulsory Licences for Export of Medicines
    • Options for Regional Economic Communities
    • Voluntary Licences
  • TRIPS Flexibilities Database
  • Resources
    • Briefs & Briefing Documents
    • Publications
    • Tools
    • Useful Links
    • All Resources
  • Blog
  • About

Tag: HIV

CJEU Ruling on Truvada recalls ‘evergreening’ goes against public health interests

Pascale Boulet - September 10, 2018

How patents, data exclusivity and SPCs interact to extend market exclusivity...

Pascale Boulet - July 10, 2018

Dolutegravir Patent Licences Can Provide Access To All

Ellen 't Hoen - July 26, 2017

Recent Posts

  • BMJ Commentary: Overriding drug and medical technology patents for pandemic recovery: a legitimate move for high-income countries, too
  • Ensuring that intellectual property rights aren’t a barrier to scaling-up: the remarkable example of penicillin production in the United States during World War II.
  • Dutch Health Care Institute Says No to Medicines Pirate
  • We need a Global Vaccines Taskforce, not just a British or European one

Posts by Subject

Access to Medicines ARIPO C-TAP Cancer CDCA competition law Compulsory licensing compulsory licensing for export covid-19 Covid-19 Pool Data exclusivity Delinkage DNDi dolutegravir European Commission European Union evergreening Fair Pricing Gilead Hepatitis C HIV IFPMA LDCs market exclusivity Medicines Patent Pool Medicines Pricing Netherlands orkambi Orphan Drugs Patents PrEP R&D remdesivir Sofosbuvir SPC Supplementary Protection Certificates The Netherlands transparency TRIPS Council TRIPS flexibilities Truvada vaccines WHO WIPO WTO
Medicines Law & Policy releases analysis, policy recommendations and tools to aid practitioners working on universal access to medicines. We strive to provide information that is as accurate as possible, and we welcome and encourage feedback. For comments or questions contact us at: info@medicineslawandpolicy.net.
  • Home
  • Covid-19
  • Tools
    • Introduction to the Tools
    • Model Government Use Licences
    • Model Uses of Paragraph 7 or “LDC Waiver”
    • Special Compulsory Licences for Export of Medicines
    • Options for Regional Economic Communities
    • Voluntary Licences
  • TRIPS Flexibilities Database
  • Resources
    • Briefs & Briefing Documents
    • Publications
    • Tools
    • Useful Links
    • All Resources
  • Blog
  • About
 This work is licensed under Creative Commons.